Employees: 03 (2023.0)Legal category: 5485Size: PMECreation date: 2011-08-04 (14 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: FEIGNIES (59750), Nord
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
PHARMACIE LINXE : revenue, balance sheet and financial ratios
PHARMACIE LINXE is a French company
founded 14 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in FEIGNIES (59750),
this company of category PME
shows in 2024 a net income positive of 82 k€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE LINXE (SIREN 534044508)
Indicator
2024
2023
2022
2021
2020
2019
2018
2017
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net income
81 941 €
151 486 €
257 165 €
240 156 €
169 014 €
143 029 €
134 302 €
139 383 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2024, PHARMACIE LINXE generates positive net income of 82 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2024: 139 k€ -> 82 k€.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
81 941 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 44%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 60%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
44.246%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
59.533%
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
Debt ratio
126.937
114.268
79.547
67.943
47.097
46.571
9.537
44.246
Financial autonomy
38.778
40.174
48.087
51.241
57.135
59.086
78.034
59.533
Repayment capacity
None
None
None
None
None
None
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
44.252024
2022
2023
2024
Q1: 16.45
Med: 58.41
Q3: 154.59
Good+6 pts over 3 years
In 2024, the debt ratio of PHARMACIE LINXE (44.25) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
59.53%2024
2022
2023
2024
Q1: 28.92%
Med: 49.95%
Q3: 69.49%
Good
In 2024, the financial autonomy of PHARMACIE LINXE (59.5%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 199.96. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
199.964
Liquidity indicators evolution PHARMACIE LINXE
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
Liquidity ratio
277.443
211.179
242.842
242.943
0.0
0.0
0.0
199.964
Interest coverage
None
None
None
None
None
None
None
None
Sector positioning
Liquidity ratio
199.962024
2022
2023
2024
Q1: 129.47
Med: 182.14
Q3: 260.79
Good+54 pts over 3 years
In 2024, the liquidity ratio of PHARMACIE LINXE (199.96) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Positioning of PHARMACIE LINXE in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of PHARMACIE LINXE is estimated at
1 143 956 €
(range 796 633€ - 1 711 425€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
796k€1143k€1711k€
1 143 956 €Range: 796 633€ - 1 711 425€
NAF 5 année 2024
Valuation method used
Net Income Multiple
81 941 €
×
14.0x
=1 143 957 €
Range: 796 634€ - 1 711 425€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE LINXE with other companies in the same sector:
The revenue of PHARMACIE LINXE is not publicly disclosed (confidential accounts filed with INPI).
Is PHARMACIE LINXE profitable?
Yes, PHARMACIE LINXE generated a net profit of 82 k€ in 2024.
Where is the headquarters of PHARMACIE LINXE ?
The headquarters of PHARMACIE LINXE is located in FEIGNIES (59750), in the department Nord.
Where to find the tax return of PHARMACIE LINXE ?
The tax return of PHARMACIE LINXE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE LINXE operate?
PHARMACIE LINXE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart